Market cap
$19.2m
End-of-day close multiplied by current shares on issue.
BLT · NZX
BLIS Technologies is an NZX-listed healthcare / biotechnology company with HY23 - FY26 of published result briefings.
Snapshot
FY26, released 21 May 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $14.7m | ↑ +16.0% |
| NPAT | $0.7m | ↓ -12.5% |
| Operating cash flow | -$0.6m | ↓ -133.2% |
| Net debt | -$4m | — |
| ROE % | 5.3% | ↓ -1.5pp |
| PBT | $0.8m | ↓ -11.1% |
| FCF pre-lease | -$1.1m | ↓ -166.0% |
| Debtor days | 51 | ↑ +65.6% |
| Inventory days | 40Outside range high inventory days. 40d; 3-period range 21d to 26d. Inventory days: 39.6 days, above normal range; 3-period mean 23.3 days, range 21.0 days-26.2 days. | ↑ +88.6% |
| Total assets | $15m | ↑ +4.7% |
Source: latest published briefing (FY26, released 21 May 2026). Change compares against the prior equivalent period: FY25, released 22 May 2025.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$19.2m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
27.41x
Recent market cap compared with trailing earnings.
EPS
0.00
Recent filing-derived earnings per share.
PEG
Not available
Not meaningful without positive comparable earnings growth.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
1.47x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Indexed lines compare direction from the first positive comparable filing point. The axis is an index, not dollars or cents.
Chat
Ask follow-up questions about BLIS Technologies's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | FY2612 MONTHS21 May 2026 | HY266 MONTHS27 November 2025 | FY2512 MONTHS22 May 2025 | HY256 MONTHS26 November 2024 | FY2412 MONTHS24 May 2024 | HY246 MONTHS16 November 2023 | FY2312 MONTHS25 May 2023 | HY236 MONTHS10 November 2022 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.7m | $7.7m | $12.6m | $6m | $11.5m | $4.8m | $10.2m | $4.3m | Chart |
| Revenue growth % | 16.0%Outside range high revenue growth. 16%; 3-period range 9.7% to 14.2%. Revenue growth: 16.0%, above normal range; 3-period mean 12.2%, range 9.7%-14.2%. | 28.1%Outside range high revenue growth. 28.1%; 3-period range 10.2% to 25.4%. Revenue growth: 28.1%, above normal range; 3-period mean 15.7%, range 10.2%-25.4%. | 9.7%Outside range low revenue growth. 9.7%; 3-period range 12.6% to 16%. Revenue growth: 9.7%, below normal range; 3-period mean 14.3%, range 12.6%-16.0%. | 25.4% | 12.6% | 11.4% | 14.2% | 10.2%Outside range low revenue growth. 10.2%; 3-period range 11.4% to 28.1%. Revenue growth: 10.2%, below normal range; 3-period mean 21.6%, range 11.4%-28.1%. | Chart
|
| EBITDA | — | $0.5m | $1m | — | $0.8m | — | — | — | Chart |
| EBITDA margin % | — | 6.5% | 7.9% | — | 6.9% | — | — | — | Chart |
| PBT | $0.8m | $0.4m | $0.9m | $0.2m | $0.7m | -$0.7m | -$1.3m | -$1.7m | Chart |
| PBT growth % | -11.1%Outside range low pbt growth. -11.1%; 3-period range 28.6% to 151.6%. PBT growth: -11.1%, below normal range; 3-period mean 76.8%, range 28.6%-151.6%. | 100.0% | 28.6% | — | — | — | — | — | Chart
|
| NPAT | $0.7m | $0.4m | $0.8m | $0.2m | $0.6m | -$0.7m | -$1.3m | -$1.7m | Chart |
| NPAT growth % | -12.5%Outside range low npat growth. -12.5%; 3-period range 33.3% to 147.9%. NPAT growth: -12.5%, below normal range; 3-period mean 77.1%, range 33.3%-147.9%. | 100.0% | 33.3% | — | — | — | — | — | Chart
|
| Operating cash flow | -$0.6m | -$0.49m | $1.8m | $0.74m | $1.1m | -$0.04m | $0.11m | $0.35m | Chart |
| OCF / EBITDA % | — | -97.4% | 178.5% | — | 132.0% | — | — | — | Chart |
| FCF pre-lease | -$1.1m | -$0.57m | $1.7m | $0.64m | $0.49m | -$0.12m | $0.06m | $0.31m | Chart |
| FCF post-lease | — | — | $1.7m | — | — | — | — | — | — |
| ROE % | 5.3% | 3.1% | 6.8% | 2.0% | 5.8% | -6.6% | -12.0% | -14.4% | Chart |
| Net debt | -$4m | — | — | — | -$4.3m | -$3.9m | -$4.3m | -$8.7m | Chart |
| Net debt / EBITDA | — | — | — | — | -5.35x | — | — | — | — |
| Debtor days | 51 | 33 | 31Outside range low debtor days. 31d; 3-period range 41d to 52d. Debtor days: 30.5 days, below normal range; 3-period mean 47.7 days, range 41.0 days-51.6 days. | 32 | 41 | 38Outside range high debtor days. 38d; 3-period range 22d to 33d. Debtor days: 37.9 days, above normal range; 3-period mean 28.7 days, range 21.6 days-32.9 days. | 52Outside range high debtor days. 52d; 3-period range 31d to 51d. Debtor days: 51.6 days, above normal range; 3-period mean 40.7 days, range 30.5 days-50.5 days. | 22Outside range low debtor days. 22d; 3-period range 32d to 38d. Debtor days: 21.6 days, below normal range; 3-period mean 34.2 days, range 31.7 days-37.9 days. | Chart
|
| Inventory days | 40Outside range high inventory days. 40d; 3-period range 21d to 26d. Inventory days: 39.6 days, above normal range; 3-period mean 23.3 days, range 21.0 days-26.2 days. | 91 | 21Outside range low inventory days. 21d; 3-period range 23d to 40d. Inventory days: 21.0 days, below normal range; 3-period mean 29.5 days, range 22.8 days-39.6 days. | 50 | 23 | 31 | 26 | 32 | Chart
|
| Total assets | $15m | $14.8m | $14.3m | $13.4m | $12.9m | $12m | $12.8m | $12.4m | Chart |
Reference: annolyse.ai/companies/blt
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Free cash flow after lease payments where available.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
From Revenue grew 28.1% but operating cash swung negative on inventory build
Annolyse's historical second-half shape is informative: HY25 represented only 47.4% of FY25 revenue, 29.9% of FY25 EBITDA and 27.3% of FY25 NPAT, so BLIS is materially 2H-weighted. Annualising HY26 revenue gives $15.3m, but applying the prior shape implies a stronger full-year revenue outturn. No company-stated targets are provided.
The release notes a further $0.1m of one-off costs to be released, implying some additional cost normalisation in 2H, and the inventory build may be deliberate positioning for the heavier half. Whether 2H revenue and cash conversion follow the historical pattern is the central uncertainty this release does not resolve.
Open questions
This briefing cannot assess whether the inventory build is positioning for 2H demand or evidence of slowing sell-through, because the release does not disclose stock composition or order cover.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
FY26 · Released 21 May 2026
A NZ$1.8m working-capital build—versus a historical average release of NZ$0.2m—consumed all reported profit and then some, turning free cash flow
HY26 · Released 27 November 2025
A $1.4m working-capital absorption pushed HY26 operating cash flow to -$0.5m, contradicting the $0.5m EBITDA and PBT-doubling headline.
FY25 · Released 22 May 2025
Earnings grew on operating leverage and cash conversion strengthened to 178%, but 73% of NPAT and nearly all operating cash flow landed in the second
HY25 · Released 26 November 2024
HY25 swung from a NZ$0.7m loss to a NZ$0.2m profit, but the prior year's heavy second-half skew sets a demanding bar for FY25.
FY24 · Released 24 May 2024
FY24 NPAT of $0.6m swung from a $1.3m loss on 18.2% B2B growth, with the first half a $0.7m loss and the second half doing all the work.
HY24 · Released 16 November 2023
Revenue grew 11.4% yet receivables almost doubled and debtor days hit 37.9, well above the historical mean of 28.7.
FY23 · Released 25 May 2023
Operating cash flow flipped positive and H2 turned profitable, yet the cash balance fell $4.2m versus only $0.1m of OCF — a reconciliation gap that
HY23 · Released 10 November 2022
Revenue grew 10.2% under the strategy reset, but operating cash was flattered by debtor and inventory releases that broke the historical build
Get the next BLIS Technologies result briefing and five-year history updates by email.